Literature DB >> 10722742

Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.

S Fang1, J P Jensen, R L Ludwig, K H Vousden, A M Weissman.   

Abstract

Mdm2 has been shown to regulate p53 stability by targeting the p53 protein for proteasomal degradation. We now report that Mdm2 is a ubiquitin protein ligase (E3) for p53 and that its activity is dependent on its RING finger. Furthermore, we show that Mdm2 mediates its own ubiquitination in a RING finger-dependent manner, which requires no eukaryotic proteins other than ubiquitin-activating enzyme (E1) and an ubiquitin-conjugating enzyme (E2). It is apparent, therefore, that Mdm2 manifests an intrinsic capacity to mediate ubiquitination. Mutation of putative zinc coordination residues abrogated this activity, as did chelation of divalent cations. After cation chelation, the full activity could be restored by addition of zinc. We further demonstrate that the degradation of p53 and Mdm2 in cells requires additional potential zinc-coordinating residues beyond those required for the intrinsic activity of Mdm2 in vitro. Replacement of the Mdm2 RING with that of another protein (Praja1) reconstituted ubiquitination and proteasomal degradation of Mdm2. However, this RING was ineffective in ubiquitination and proteasomal targeting of p53, suggesting that there may be specificity at the level of the RING in the recognition of heterologous substrates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722742     DOI: 10.1074/jbc.275.12.8945

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  386 in total

1.  p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.

Authors:  A Ito; C H Lai; X Zhao; S Saito; M H Hamilton; E Appella; T P Yao
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

2.  The RING-H2 finger protein APC11 and the E2 enzyme UBC4 are sufficient to ubiquitinate substrates of the anaphase-promoting complex.

Authors:  M Gmachl; C Gieffers; A V Podtelejnikov; M Mann; J M Peters
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

3.  Identification of multiple CDH1 homologues in vertebrates conferring different substrate specificities.

Authors:  Y Wan; M W Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

4.  Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.

Authors:  Stijn Heessen; Ainars Leonchiks; Natalia Issaeva; Anatoly Sharipo; Galina Selivanova; Maria G Masucci; Nico P Dantuma
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

5.  RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome.

Authors:  T I Cornu; J C de la Torre
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 6.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

7.  Comparative genomics and evolution of proteins involved in RNA metabolism.

Authors:  Vivek Anantharaman; Eugene V Koonin; L Aravind
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

8.  Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms.

Authors:  R Stad; N A Little; D P Xirodimas; R Frenk; A J van der Eb; D P Lane; M K Saville; A G Jochemsen
Journal:  EMBO Rep       Date:  2001-10-17       Impact factor: 8.807

Review 9.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

10.  In vivo action of the HRD ubiquitin ligase complex: mechanisms of endoplasmic reticulum quality control and sterol regulation.

Authors:  R G Gardner; A G Shearer; R Y Hampton
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.